HENGRUI PHARMA stated that while secondary market fluctuations are influenced by multiple factors, the company's operational performance continues to improve steadily, with an overall positive development trend. For the full year 2025, the company achieved operating revenue of 31.629 billion yuan, representing a year-on-year increase of 13.02%. Net profit attributable to shareholders of the listed company reached 7.711 billion yuan, a year-on-year increase of 21.69%. In the first quarter of 2026, operating revenue was 8.141 billion yuan, up 12.98% year-on-year, with net profit attributable to shareholders of the listed company at 2.282 billion yuan, an increase of 21.78% year-on-year. The company consistently places high importance on the interests of all shareholders, is committed to developing its core business, promoting sustainable performance growth, and rewarding shareholders through continued progress.